Myasthenia gravis: open trials in Germany

22 open trials have a site in Germany. Registry data; only the trial team decides who can take part.

NCT07463521
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Trial Treatment · Phase 3 · UCB Biopharma SRL
Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil gGmbH, Bochum · Universitaetsklinikum Essen (AoR), Essen · Universitaetsmedizin Goettingen, Goettingen · Universitaetsklinikum Jena KöR, Jena · Universitaet Leipzig, Leipzig · Immanuel Klinik Ruedersdorf, Rüdersdorf · Universitaetsklinikum Wuerzburg AöR, Wuerzburg
Registry updated 2026-11-06
NCT07465289
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Trial Treatment · Phase 3 · UCB Biopharma SRL
Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil gGmbH, Bochum · Universitaetsklinikum Essen (AoR), Essen · Universitaetsmedizin Goettingen, Goettingen · Universitaetsklinikum Jena KöR, Jena · Universitaet Leipzig, Leipzig · Immanuel Klinik Ruedersdorf, Rüdersdorf · Universitaetsklinikum Wuerzburg AöR, Wuerzburg
Registry updated 2026-11-06
NCT04951622
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Charite Universitaetsmedizin Berlin KöR, Berlin · Universitaetsmedizin Goettingen, Goettingen · Universitaetsklinikum Ulm AoR, Ulm
Registry updated 2026-11-05
NCT07323316
Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
Trial Treatment · Ad scientiam
Charité Berlin, Berlin · Universitätsklinikum Bergmannsheil Bochum, Bochum · LMU Klinikum, München
Registry updated 2026-11-05
NCT07673627
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Trial Treatment · Phase 2 · argenx
Klinikum Altenburger Land GmbH, Altenburg · Charite Universitaetsmedizin Berlin KöR, Berlin · Universitaetsmedizin Goettingen, Goettingen · Universitaetsklinikum Wuerzburg AöR, Wuerzburg
Registry updated 2026-11-04
NCT05374590
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Trial Treatment · Phase 2/3 · argenx
Charite Universitaetsmedizin Berlin KöR, Berlin · Universitaetsklinikum Essen (AoR), Essen
Registry updated 2026-11-03
NCT07217587
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Klinikum Altenburger Land GmbH, Altenburg · Katholisches Klinikum Bochum gGmbH, Bochum · Universitaetsklinikum Erlangen AöR, Erlangen · Medical Center- University of Freiburg, Freiburg im Breisgau · Universitaet Muenster, Muenster · Immanuel Klinik Ruedersdorf, Rüdersdorf
Registry updated 2026-11-03
NCT07647510
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Trial Treatment · Phase 3 · Dianthus Therapeutics
Medical Center- University of Freiburg, Freiburg im Breisgau
Registry updated 2026-10-30
NCT07294170
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Research · argenx
Charité Universitätsmedizin Berlin, Berlin · Universitätsmedizin Göttingen, Göttingen · Universitätsklinikum Würzburg, Würzburg
Registry updated 2026-10-26
NCT06463587
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Trial Treatment · Phase 3 · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Charite Universitaetsmedizin Berlin KöR, Berlin · St. Josef Hospital, Bochum · Technische Universitaet Dresden, Dresden · Universitaetsklinikum Duesseldorf AöR, Duesseldorf · Universitaetsmedizin Goettingen, Goettingen · Klinikum Oberberg GmbH, Gummersbach · Medizinische Hochschule Hannover, Hanover · Universitaet Leipzig, Leipzig · Universitaetsklinikum Schleswig-Holstein AöR, Luebeck · Universitaetsklinikum Ulm AoR, Ulm
Registry updated 2026-10-21
NCT06392386
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Trial Treatment · Phase 2/3 · argenx
Universitaetsklinikum Essen (AoR), Essen
Registry updated 2026-09-28
NCT07284420
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Trial Treatment · Phase 2 · argenx
Klinikum Altenburger Land GmbH, Altenburg · Charite Universitaetsmedizin Berlin KöR, Berlin · Universitaetsmedizin Goettingen, Goettingen · Universitaetsklinikum Wuerzburg AöR, Wuerzburg
Registry updated 2026-09-24
2024-515627-10-00
A double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis
Trial Treatment · Phase 1/2 · Bonsai Biotherapeutics AB
University Medical Center Hamburg-Eppendorf, Hamburg · Universitaet Muenster, Muenster · Klinikum der Technischen Universitaet Muenchen (TUM Klinikum), Munich
Registry updated 2026-09-09
NCT07039916
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Trial Treatment · Phase 3 · Immunovant Sciences GmbH
Katholisches Klinikum Bochum gGmbH, Bochum · Universitaetsklinikum Essen (AoR), Essen · Universitaetsmedizin Goettingen, Goettingen · Otto Von Guericke Universitaet Magdeburg, Magdeburg · Klinikum Wuerzburg Mitte gGmbH, Wuerzburg
Registry updated 2026-07-30
NCT06193889
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Trial Treatment · Phase 2/3 · Kyverna Therapeutics
Charite Universitaetsmedizin Berlin KöR, Berlin · St. Josef Hospital, Bochum · University Medical Center Hamburg-Eppendorf, Hamburg · Medizinische Hochschule Hannover, Hanover · Universitaetsklinikum Jena KöR, Jena · Universitaetsklinikum Magdeburg AöR, Magdeburg · Klinikum der Technischen Universitaet Muenchen (TUM Klinikum), Munich
Registry updated 2026-07-29
NCT06312644
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Research · Alexion Pharmaceuticals, Inc.
Essen
Registry updated 2026-04-16
NCT07221838
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
Trial Treatment · Phase 4 · Alexion Pharmaceuticals, Inc.
Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil gGmbH, Bochum
Registry updated 2026-04-09
NCT04202341
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Research · Alexion Pharmaceuticals, Inc.
Hanover
Registry updated 2026-02-18
NCT06298565
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Research · argenx
Klinikum Altenburger Land GmbH, Altenburg · St. Josef-Hospital Klinikum der Ruhr Universitaet Bochum, Bochum · Klinikum Christophsbad, Göppingen · Georg-August-Universität Göttingen, Göttingen · Klinikum Oberberg, Gummersbach · Universitätsklinikum Jena, Jena · Universitätsklinikum Würzburg, Würzburg
Registry updated 2026-02-17
NCT06299748
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
Research · argenx
Klinikum der Ruhr-Universität Bochum St. Josef Hospital Neurologische Interdisziplinäre Infusionsambulanz + MS Studienambulanz (Haus E Ebene1), Bochum
Registry updated 2026-02-17
NCT07403188
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Research · Phase 2/3 · Kyverna Therapeutics
Charite Universitaetsmedizin Berlin KöR, Berlin · Katholisches Klinikum Bochum gGmbH, Bochum · Leibniz Institute Of Virology, Hamburg · Medizinische Hochschule Hannover, Hanover
Registry updated 2026-02-11
NCT06605612
Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders
Research · LMU Klinikum
Friedrich-Baur-Institut, Neurologische Klinik und Poliklinik, LMU Klinikum, Ludwig-Maximilians-Universität München, München
Registry updated 2025-09-10

All Myasthenia gravis trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error